TableĀ 2

IRs and SIRs for all malignancies (excluding NMSC), lymphoma, lung and breast cancer for tofacitinib-treated patients with RA (across phase II, III and LTE studies)

IR Events/100 py (95% CI)SIR26* (95% CI)
All malignancies (excluding NMSC)0.85 (0.70 to 1.02)1.17 (0.96 to 1.41)
Lymphoma0.08 (0.04 to 0.14)2.64 (1.27 to 4.86)
Lung cancer0.19 (0.13 to 0.28)2.19 (1.39 to 3.29)
Breast cancer0.18 (0.12 to 0.28)0.78 (0.47 to 1.22)
  • Tofacitinib data up to 10 April 2013.

  • *SEER database (US General Population), SIR data adjusted for age and sex.

  • IR, incidence rate; LTE, long-term extension; NMSC, non-melanoma skin cancer; py, patient-years; RA, rheumatoid arthritis; SEER, Surveillance Epidemiology and End Result; SIR, standardised incidence ratio as compared with the SEER database.